Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07213674 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Name: A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer — clinical trial record (NCT07213674)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorAmgen

Started2025-11-28

View on ClinicalTrials.gov ↗

The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).

Amendment history 7 changes detected by DataLookout

2026-08-14

Trial sites expanded: 144 → 149 locations

2026-07-25

Trial sites expanded: 140 → 144 locations

2026-07-17

Trial sites expanded: 136 → 140 locations

2026-06-05

Trial sites expanded: 129 → 133 locations

2026-04-25

Trial sites expanded: 122 → 125 locations

2026-04-10

Trial sites expanded: 117 → 120 locations

2026-03-31

Trial sites expanded: 94 → 116 locations

Trial Details

NCT Number	NCT07213674
Lead Sponsor	Amgen
Conditions	Metastatic Castration-resistant Prostate Cancer
Enrollment	750 participants
Start Date	2025-11-28
Primary Completion	2030-01-07 (estimated)
Study Completion	2032-08-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-27